Overview Performance Dividends Peer Group Options

(BCLI) Brainstorm Cell - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US10501E2019

BCLI: Cell Therapies, Neurotrophic Factors, Autologous Cells

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a biotechnology company specializing in the development of innovative autologous cellular therapies for neurodegenerative diseases. The companys proprietary NurOwn platform harnesses the potential of mesenchymal stem cells derived from patients own bone marrow. These cells are cultured under specific conditions to enhance their secretion of neurotrophic factors, which play a critical role in modulating neuroinflammation, supporting neuronal survival, and improving neurological function. NurOwn is currently in advanced clinical trials, including a Phase III trial for amyotrophic lateral sclerosis (ALS), a Phase II trial for progressive multiple sclerosis (MS), and preclinical studies for Alzheimers disease and other neurodegenerative disorders. The company, founded in 2000 and headquartered in New York, focuses on addressing unmet medical needs in neurology through its groundbreaking cell therapy approach.

Web URL: https://www.brainstorm-cell.com

Ticker Symbol: BCLI Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Average Volume 20d: 27388 Last Price: 1.60 SMA 20: 1.68 SMA 50: 1.93 SMA 200: 3.47 ATR: 0.15 Market Cap: 9.13M USD P/E: 0.00 P/E Forward: 0.00 P/B: 65.82 P/S: 0.00 RoE: 163.05 3-Month Forecast: Based on and , BCLIs stock is expected to face headwinds in the near term. The stock is trading below its 20-, 50-, and 200-day moving averages, indicating bearish momentum. The low average volume and ATR suggest limited market activity and volatility. However, the companys progress in clinical trials, particularly for NurOwn, could act as a catalyst for upside movement. With a high P/B ratio and negative earnings, investors should monitor the companys cash burn rate and clinical trial outcomes closely.

Additional Sources for BCLI Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BCLI Stock Overview

Market Cap in USD 7m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2003-08-28

BCLI Stock Ratings

Growth Rating -92.1
Fundamental -
Dividend Rating 0.0
Rel. Strength -80.4
Analysts 4/5
Fair Price Momentum 0.65 USD
Fair Price DCF -

BCLI Dividends

No Dividends Paid

BCLI Growth Ratios

Growth Correlation 3m -85.3%
Growth Correlation 12m -91%
Growth Correlation 5y -94.8%
CAGR 5y -57.72%
CAGR/Max DD 5y -0.58
Sharpe Ratio 12m -2.95
Alpha -88.97
Beta 0.284
Volatility 136.52%
Current Volume 117.8k
Average Volume 20d 106.9k
What is the price of BCLI stocks?
As of May 11, 2025, the stock is trading at USD 1.18 with a total of 117,801 shares traded.
Over the past week, the price has changed by -6.35%, over one month by +5.88%, over three months by -31.40% and over the past year by -83.15%.
Is Brainstorm Cell a good stock to buy?
No, based on ValueRay Analyses, Brainstorm Cell (NASDAQ:BCLI) is currently (May 2025) a stock to sell. It has a ValueRay Growth Rating of -92.10 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BCLI as of May 2025 is 0.65. This means that BCLI is currently overvalued and has a potential downside of -44.92%.
Is BCLI a buy, sell or hold?
Brainstorm Cell has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy BCLI.
  • Strong Buy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BCLI stock price target?
According to ValueRays Forecast Model, BCLI Brainstorm Cell will be worth about 0.7 in May 2026. The stock is currently trading at 1.18. This means that the stock has a potential downside of -39.83%.
Issuer Forecast Upside
Wallstreet Target Price 13.1 1011.9%
Analysts Target Price 23.5 1887.3%
ValueRay Target Price 0.7 -39.8%